The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

show that semaglutide improved quality of life and increased the distance that participants could walk without the debilitating calf cramping that is a hallmark of peripheral artery disease ...